SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense community focus as investors weigh upcoming Phase 3 data catalysts for its lead psychiatric programs against concerns over cash burn and potential dilution. While some traders are bullish on the stock's clinical potential and institutional backing, others are actively debating management's track record and the long-term scalability of their psychedelic-based treatment models.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is trending as the community debates its technical performance and growth potential against a backdrop of ongoing antitrust litigation regarding its rental listing practices. Investors are actively discussing the company's valuation, potential upside from AI-driven integrations with ChatGPT, and its ability to maintain dominance in the housing sector amid regulatory scrutiny.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidia is currently trending as investors monitor rapid Yutrepia product adoption and positive sales growth, while the community closely debates the potential impact of ongoing patent litigation and M&A speculation. Shareholders are largely focused on the company's competitive position against market peers and the anticipation of a pivotal legal ruling that could significantly shift the stock's valuation.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors debate its long-term potential, with bulls pointing to the brand's expanding real-world retail footprint and unique IP partnerships as reasons for optimism. While some community members remain frustrated by stagnant price action compared to the broader crypto market, others are actively accumulating tokens, betting that its utility and mainstream cultural reach will drive significant future gains.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is trending as investors monitor its pipeline and strategic moves in the obesity and immunology sectors, while the community heavily debates potential M&A activity involving the company and clinical-stage assets. Traders are actively discussing technical support levels and volume patterns alongside ongoing speculation about the company's competitive positioning against other major pharmaceutical firms.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve Cannabis Corp is currently trending as the first major U.S. cannabis company to uplist to the NYSE, a milestone that has triggered intense discussion regarding institutional liquidity and potential regulatory shifts. The community is actively debating the company's valuation and strategic direction following the recent departure of a top executive, while closely monitoring market volatility related to broader sector index rebalancing.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is currently a focal point for investors debating whether its deeply depressed valuation at low forward price-to-earnings multiples represents a historic buying opportunity or a structural value trap in the face of legacy fintech disruption. While some market participants are aggressively accumulating shares and citing institutional backing, others are actively dumping the stock due to stalled revenue growth, high debt levels, and frustration over the company's long-term performance.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is currently a major focus for traders as they anticipate the upcoming Q1 earnings report and critical interim Phase 1 clinical data for its lead candidate, ABCL635. While the community is actively debating the stock's long-term potential versus its history of underperformance, strong institutional accumulation and notable analyst upgrades are driving significant volume and heightened short-interest volatility.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as investors debate its long-term enterprise utility and corporate governing council structure against ongoing concerns regarding token supply dilution. The community remains deeply divided, with some actively accumulating at current levels in anticipation of regulatory developments and institutional adoption, while others express frustration over stagnant price action.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending due to investor discourse surrounding the fund's recent 1-for-10 reverse stock split and a strategic shift in holdings toward large-cap blue chips to combat ongoing NAV erosion. The community remains deeply divided, with some investors focusing on high yield and potential recovery, while others criticize the fund's performance and payout volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novartis Reports Positive Data for Neuromuscular Disorder Drug 

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.

EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention

BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.

BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.

Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now

IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer

Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer are benefiting from innovation, pipeline growth and strong demand in key therapies.

4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates

In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.

BAYRY's Kerendia Label Expansion Application Gets Priority Review 

Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Current Price	$10.44
Prev Close	$10.40
Open	$10.36
Dividend Yield	0.21%
50-Day Moving Average	$11.05
Beta	0.46
Avg. Volume	1.74M
PE Ratio	-16.47

52-Week High	$14.85
52-Week Low	$7.19
Market Capitalization	$41.03B
EPS (Annual)	-$1.04
Price to Book	1.23
Revenue Per Employee	$583,970.35

BAYRYBayer AG (ADR)

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BAYRY News